Literature DB >> 11095827

Quinupristin-Dalfopristin.

.   

Abstract

The incidence of infection with multidrug-resistant or pan-resistant gram-positive bacteria has drastically limited or eliminated the conventional antimicrobial options available to clinicians. Quinupristin-dalfopristin, a unique parenteral streptogramin that lacks cross-resistance with other antimicrobials, has shown clinical efficacy against many of these important bacteria. This review focuses on quinupristin-dalfopristin"s mechanism of action, in vitro spectrum of activity, clinical efficacy and toxicity, and likely future role in the management of serious gram-positive infections.

Entities:  

Year:  1999        PMID: 11095827     DOI: 10.1007/s11908-999-0062-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  38 in total

1.  A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500.

Authors:  S D Etienne; G Montay; A Le Liboux; A Frydman; J J Garaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

Review 2.  Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

3.  Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  M Pujol; X Corbella; C Peña; R Pallares; J Dorca; R Verdaguer; A Diaz-Prieto; J Ariza; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

4.  Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure.

Authors:  S A Nachman; R Verma; M Egnor
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

5.  Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.

Authors:  S A Marshall; W W Wilke; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-03       Impact factor: 2.803

6.  Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin.

Authors:  W A Lynn; E Clutterbuck; S Want; V Markides; S Lacey; T R Rogers; J Cohen
Journal:  Lancet       Date:  1994-10-08       Impact factor: 79.321

Review 7.  A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.

Authors:  C Bébéar; D H Bouanchaud
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

8.  The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.

Authors:  R C Moellering; P K Linden; J Reinhardt; E A Blumberg; F Bompart; G H Talbot
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

9.  Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae.

Authors:  T Q Tan; E O Mason; W J Barson; E R Wald; G E Schutze; J S Bradley; M Arditi; L B Givner; R Yogev; K S Kim; S L Kaplan
Journal:  Pediatrics       Date:  1998-12       Impact factor: 7.124

Review 10.  Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

Authors:  M Dowzicky; H L Nadler; C Feger; G Talbot; F Bompart; M Pease
Journal:  Am J Med       Date:  1998-05-29       Impact factor: 4.965

View more
  1 in total

1.  Prevalence and antimicrobial resistance of Enterococcus species: a hospital-based study in China.

Authors:  Wei Jia; Gang Li; Wen Wang
Journal:  Int J Environ Res Public Health       Date:  2014-03-21       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.